Please login to the form below

Not currently logged in

Vibativ is granted marketing authorisation

European marketing authorisation has been granted for Vibativ, a once-daily injection to treat hospital acquired nosocomial pneumonia

Astellas Pharma Europe and Theravance have announced that the European Medicines Agency (EMA) has granted marketing authorisation for Vibativ (telavancin hydrochloride), used to treat hospital-acquired nosocomial pneumonia via a once-daily bactericidal injection.

The authorisation follows a positive opinion from the Committee for Human Medicinal Products (CHMP) and grants the treatment of adults in Europe with nosocomial pneumonia including ventilator-associated pneumonia, known or suspected to be caused by MRSA. It has been granted for when other alternatives are not suitable.

Vibativ is a once-daily injectable lipoglycopeptide antibacterial agent that has a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).

Vibativ provides an "effective hospital antibiotic option for patients with hospital-acquired pneumonia caused by MRSA" stated Ken Jones, president and CEO of Astellas Pharma Europe.

15th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....